Skip to search formSkip to main contentSkip to account menu

infliximab-dyyb 100 MG Injection [Inflectra]

Known as: INFLIXIMAB 100 mg in 10 mL INTRAVENOUS INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION [INFLECTRA], Inflectra 100 MG Injection 
National Institutes of Health

Related topics

Related topics

7 relations
InflectraInjectionPolysorbate 80Sucrose

Broader (2)

infliximab Injection [Inflectra]infliximab-dyyb 100 MG Injection

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2019
Review
2019
Can We Extrapolate Data from One Immune-Mediated Inflammatory Disease to Another One?
Immune-mediated inflammatory diseases share several pathogenic pathways and this pushes sometimes to extrapolate from one disease… 
2018
2018
Kosten-Nutzwert-Analyse der Biosimilar-Therapie bei ankylosierender Spondylitis in Deutschland
Zusammenfassung Hintergrund Tumornekrosefaktor-α-Inhibitoren für die Behandlung entzündlich-rheumatischer Erkrankungen gehören zu… 
2017
2017
P632 Comparative analysis of the pharmacokinetics of Inflectra® biosimilar with Remicade® in the induction phase of remission in patients with Crohn's disease.
2015
2015
CT-P13 (an infliximab biosimilar): a guide to its use in the EU
CT-P13 (Remsima™; Inflectra™) is an infliximab biosimilar approved in the EU for use in all indications for which reference… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)